Penny Hawkins, James Dooley, Jessica Rodda, Colin Gilbert
This report presents findings from a group of UK-based researchers with expertise in the use of animal models for bone marrow ablation and reconstitution. The primary aim is to facilitate the implementation of the Three Rs (Replacement, Reduction and Refinement), with an emphasis on refinement. Bone marrow ablation and reconstitution procedures are performed for a number of different purposes and conducted predominantly in mice. These procedures can induce significant suffering, classified as "severe", Category E or Category D/E under European, US and Canadian legislation, respectively. Although severity categorization is not mandated in countries such as Australia and New Zealand, legislation still requires that the level of animal suffering must be minimized to the greatest extent possible. This report identifies specific animal welfare issues and proposes practical measures aimed at reducing both animal use and suffering.
{"title":"Refining bone marrow ablation and reconstitution in mice","authors":"Penny Hawkins, James Dooley, Jessica Rodda, Colin Gilbert","doi":"10.1111/imcb.12847","DOIUrl":"10.1111/imcb.12847","url":null,"abstract":"<p>This report presents findings from a group of UK-based researchers with expertise in the use of animal models for bone marrow ablation and reconstitution. The primary aim is to facilitate the implementation of the Three Rs (Replacement, Reduction and Refinement), with an emphasis on refinement. Bone marrow ablation and reconstitution procedures are performed for a number of different purposes and conducted predominantly in mice. These procedures can induce significant suffering, classified as \"severe\", Category E or Category D/E under European, US and Canadian legislation, respectively. Although severity categorization is not mandated in countries such as Australia and New Zealand, legislation still requires that the level of animal suffering must be minimized to the greatest extent possible. This report identifies specific animal welfare issues and proposes practical measures aimed at reducing both animal use and suffering.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":"103 3","pages":"293-306"},"PeriodicalIF":3.2,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12847","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pursuing an international scientific career is a fantastic opportunity for personal and professional growth, but it also poses unique challenges, which can be particularly daunting for researchers coming from resource-limited countries. Drawing from personal experience, this article provides insights into navigating the transition to working abroad in academia and developing a sustainable career while integrating into a new culture. From predeparture preparations to achieving career independence, I discuss practical aspects of crafting tailored applications to contact potential advisers, contemplating visa-related challenges, establishing collaborations and emphasizing the value of finding appropriate mentorship to help you adapt to new cultural and professional environments. The article also underscores the importance of resilience, adaptability and redefining career success as a dynamic, nonlinear process. I present an original perspective on career planning, inspired by maritime voyage planning, to address the complexities of balancing personal and professional life, particularly during transitional periods. This approach, which combines four key stages of planning, namely, appraisal, planning, execution and monitoring, serves as a model for early-career researchers to navigate the unpredictable tides of academic work and personal life abroad with the goal of sustaining progress and well-being. These reflections aim to empower scientists preparing for or adapting to international research environments, fostering resilience and adaptability for long-term success abroad.
{"title":"Learnings from ten years away from “home” as a South American immunologist in Ireland","authors":"Natalia Muñoz-Wolf","doi":"10.1111/imcb.12849","DOIUrl":"10.1111/imcb.12849","url":null,"abstract":"<p>Pursuing an international scientific career is a fantastic opportunity for personal and professional growth, but it also poses unique challenges, which can be particularly daunting for researchers coming from resource-limited countries. Drawing from personal experience, this article provides insights into navigating the transition to working abroad in academia and developing a sustainable career while integrating into a new culture. From predeparture preparations to achieving career independence, I discuss practical aspects of crafting tailored applications to contact potential advisers, contemplating visa-related challenges, establishing collaborations and emphasizing the value of finding appropriate mentorship to help you adapt to new cultural and professional environments. The article also underscores the importance of resilience, adaptability and redefining career success as a dynamic, nonlinear process. I present an original perspective on career planning, inspired by maritime voyage planning, to address the complexities of balancing personal and professional life, particularly during transitional periods. This approach, which combines four key stages of planning, namely, appraisal, planning, execution and monitoring, serves as a model for early-career researchers to navigate the unpredictable tides of academic work and personal life abroad with the goal of sustaining progress and well-being. These reflections aim to empower scientists preparing for or adapting to international research environments, fostering resilience and adaptability for long-term success abroad.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":"103 3","pages":"270-274"},"PeriodicalIF":3.2,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12849","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>In this exceptionally elegant and far-reaching study, the Arpaia lab at Columbia University engineer a probiotic <i>Escherichia coli</i> strain to eliminate cancer.<span><sup>1</sup></span></p><p>Working in two mouse models of cancer, CT26 colorectal cancer and B16F10 melanoma, Redenti <i>et al</i>.<span><sup>1</sup></span> start by identifying cancer-specific sequences. From these, they choose peptides containing (linked) MHCI and MHC II epitopes (about 25–30 amino acids long). They find that encoding a series of these in a plasmid, concatenated, but separated by five glycine-serine repeats, provides good expression of the neoantigens by <i>E. coli</i>.</p><p>They then turned to engineering EcN, a strain of <i>E. coli</i> isolated by Professor Alfred Nissle in 1917 from a young soldier resistant to infectious diarrhea.<span><sup>2</sup></span> Nissle marketed his discovery as a probiotic (Mutaflor®, still commercially available). Thus, Redenti <i>et al</i>. start with a safe, non-pathogenic <i>E. coli</i>, already extensively studied and widely used in humans (albeit orally).</p><p>Finding that their neoantigen plasmids express better in <i>E. coli</i> BL21 than in EcN, they set about modifying EcN to resemble BL21. Curing EcN of cryptic plasmids allows increased expression of the neoantigen-encoding plasmid. They then engineer deletions of two proteases: OmpT, which has roles in biofilm formation and the degradation of complement; and Lon which has pleiotropic roles within the bacterial cell, including oxygen-sensing.<span><sup>3</sup></span> Hence, deleting these proteases, not only reduced degradation of the neoantigen peptides, but also attenuates EcN. Although not discussed by the authors, deletion of the Lon protease may impede the survival of EcN in normal tissues more than in the anoxic core of the tumor, further reducing potential off-target effects. Overall, the authors show that their engineered EcN bacteria show an 80-fold increase in expression of the neoantigen peptides compared with the original EcN, and a 1000-fold increased susceptibility to phagocytosis and clearance from the blood.</p><p>In another stroke of genius, the authors next insert the gene for Listeriolysin O (LLO), a pore-forming protein which allows <i>Listeria</i> to escape into the cytosol after phagocytosis. This has two benefits: improved loading of neoantigen epitopes on MHC class I, and skewing towards a T<sub>H</sub>1 immune response after the sensing of intracytoplasmic bacteria.</p><p>The authors then turn to <i>in vivo</i> experiments to test their neoantigen-expressing, cryptic-plasmid cured, OmpT<sup>−</sup>, Lon<sup>−</sup>, LLO<sup>+</sup> EcN.</p><p>In both of the tumor models, EcN injected i.v. could consistently be cultured from tumors (3–4 days after injection), but could not be cultured from any of the other tissues tested, including the tumor-draining lymph node (TdLN). Despite this, i.v. injection of the EcN bacteria in the CT26 model was sho
在这项非常优雅和深远的研究中,哥伦比亚大学的Arpaia实验室设计了一种益生菌大肠杆菌菌株来消除癌症。Redenti等人在两种癌症小鼠模型CT26结肠直肠癌和B16F10黑色素瘤中进行研究,首先确定癌症特异性序列。从中,他们选择含有(连接的)MHCI和MHC II表位(约25-30个氨基酸长)的肽。他们发现,在一个质粒中编码一系列这些抗原,它们连接在一起,但被5个甘氨酸-丝氨酸重复序列分开,可以让大肠杆菌很好地表达新抗原。然后他们转向工程EcN,这是1917年阿尔弗雷德·尼塞尔教授从一名对传染性腹泻有抵抗力的年轻士兵身上分离出的一种大肠杆菌尼塞尔将他的发现作为一种益生菌(Mutaflor®,目前仍在市售)进行营销。因此,Redenti等人从一种安全的、非致病性的大肠杆菌开始,这种大肠杆菌已经被广泛研究并广泛应用于人类(尽管是口服的)。发现他们的新抗原质粒在大肠杆菌BL21中比在EcN中表达得更好,他们开始修饰EcN使其类似于BL21。固化隐质粒的EcN可以增加新抗原编码质粒的表达。然后,他们设计了两种蛋白酶的缺失:在生物膜形成和补体降解中起作用的OmpT;和在细菌细胞内具有多效性的Lon,包括氧感应因此,删除这些蛋白酶,不仅减少了新抗原肽的降解,而且减弱了EcN。尽管作者没有讨论,但Lon蛋白酶的缺失可能比在肿瘤缺氧核心更能阻碍正常组织中EcN的存活,从而进一步减少潜在的脱靶效应。总的来说,作者表明,他们的工程EcN细菌与原始EcN相比,新抗原肽的表达增加了80倍,对吞噬和血液清除的敏感性增加了1000倍。在另一个天才之笔中,作者接下来插入了李斯特菌溶素O (LLO)基因,这是一种形成孔的蛋白质,可以使李斯特菌在吞噬后逃逸到细胞质中。这有两个好处:改善MHC I类上新抗原表位的负载,以及在感知胞浆内细菌后偏向TH1免疫反应。然后,作者转向体内实验来测试他们的新抗原表达,隐质粒固化,OmpT−,Lon−,LLO+ EcN。在这两种肿瘤模型中,静脉注射的EcN可以持续地从肿瘤中培养出来(注射后3-4天),但不能从任何其他测试组织中培养出来,包括肿瘤引流淋巴结(TdLN)。尽管如此,在CT26模型中静脉注射EcN细菌被证明可以调节肿瘤和TdLN的微环境。在TdLN中,经典型树突状细胞(cDC1和cDC2s)上CD80/86表达的增加和PDL1表达的减少暗示了免疫刺激能力的增强。cDC2的百分比也增加了。在肿瘤内,治疗导致FoxP3+调节性T细胞频率降低,以及PDL1+中性粒细胞和巨噬细胞频率降低,表明免疫抑制环境减轻。IL-12的增加(典型的Th1反应,并由作者证明依赖于LLO的表达)也被检测到。这些作用不依赖于新抗原的表达,也见于不表达抗原或不相关抗原的细菌。这是否仅仅是由于细菌PAMPs,或者是否EcN表达(DNA损伤)大肠杆菌蛋白增强了这些作用,将是有趣的研究。然而,新抗原表达对于引发肿瘤特异性T细胞反应很重要:治疗后8天收集的肿瘤浸润T细胞更频繁地显示IFNγ产生,以响应新抗原肽,并且可以特异性杀死体外CT26细胞系。也有一种建议的表位扩散超出了19肽最初的目标。转向B16F10模型,作者通过体内消耗证明CD4+和CD8+ T细胞都有助于抗肿瘤反应。经表达新抗原的EcN静脉注射后,瘤内T细胞数量增加,增殖、活化和杀伤能力增强。奇怪的是,浸润cDC1、cDC2和炎症单核细胞的数量和比例的增加,以及这些细胞MHCII表达的增加似乎是抗原依赖性的:用表达不相关抗原的细菌治疗后没有发现它们。重复这些最后的实验是很重要的。总的来说,这些数据描绘了一幅令人信服的画面:减弱的细胞内细菌对先天免疫系统的有效诱导,为引发一种强大的抗原特异性T细胞反应奠定了基础,这种反应能够消除原发性和转移性癌症。 虽然许多免疫学家对给癌症患者注射细菌的第一反应可能是一种卑鄙的恐惧,但这种想法是有先例的。130年前,Coley向癌症患者静脉注射细菌。将活卡介苗(一种分枝杆菌)注入膀胱是目前治疗浅表性膀胱癌的有效方法。本实验室已在晚期癌症患者中注射了一种死分枝杆菌缓释制剂。尽管没有得到广泛认可,但有令人信服的证据表明,两种常见的癌症治疗方法,化疗和检查点抑制剂治疗也依赖于细菌——在这些情况下,依赖于肠道微生物群。6-8已知这两种疗法都会损害肠道完整性,广谱抗生素会消耗肠道细菌,从而损害两者的疗效。最近Choi等人证实了检查点抑制剂治疗后肠道细菌向肿瘤的转运[并且是我们实验室在该杂志上首次提出的假设]。因此,通过注射活细菌来治疗癌症患者,无论是静脉注射还是静脉注射,都是一种完全合理(而且确实很有灵感!)的治疗理念,而且副作用比化疗要小得多。由于人类癌症患者都有不同的MHC等位基因,每种癌症都有不同的突变,因此将Arpaia的方案转化为人类将需要一种“个性化医疗”方法。这将需要对每个患者进行MHC分型,活检,然后对其肿瘤进行测序,计算鉴定适合患者MHC的抗原表位,构建和转染质粒,然后将个性化的EcN注射到患者体内。虽然整个过程将是劳动密集型的,因此昂贵,但它是可行的:肿瘤测序和“可药物”驱动突变的鉴定正变得越来越普遍,目前正在研究mRNA癌症疫苗的类似新抗原鉴定策略。虽然Redenti等人最终关注的是静脉注射,但他们的CT26数据表明,静脉注射更有效(并且可以治愈已治疗的肿瘤和远端肿瘤)由于作者对两种治疗方法使用了相同的剂量,因此疗效的提高可能是由于更多的细菌到达肿瘤。由于大多数人类癌症都可以通过注射治疗,而且静脉注射可携带的细菌数量有限,因此不应忽视信息技术途径。这一想法的延伸可能是使用“空”EcN,或设计表达能够混杂结合人类MHCs11的常见癌症抗原的EcN;无论是单独治疗,还是与检查点疗法联合使用。当设计个性化细菌的时间和/或成本过高时(例如,在预后不良的患者中,或在发展中国家使用),这种非个性化方法将特别有用。这个引人注目的出版物为一种新颖、富有想象力和极其聪明的癌症治疗方法提供了概念证明。是时候将基于细菌的免疫疗法添加到癌症免疫治疗武器库中了!乔治·卡维奇:概念化;写作——原稿;写作——审阅和编辑。Aude M Fahrer:概念化;写作——原稿;写作——审阅和编辑。作者声明无利益冲突。
{"title":"Tumor-seeking bacterial missiles","authors":"George Cavic, Aude M Fahrer","doi":"10.1111/imcb.12844","DOIUrl":"10.1111/imcb.12844","url":null,"abstract":"<p>In this exceptionally elegant and far-reaching study, the Arpaia lab at Columbia University engineer a probiotic <i>Escherichia coli</i> strain to eliminate cancer.<span><sup>1</sup></span></p><p>Working in two mouse models of cancer, CT26 colorectal cancer and B16F10 melanoma, Redenti <i>et al</i>.<span><sup>1</sup></span> start by identifying cancer-specific sequences. From these, they choose peptides containing (linked) MHCI and MHC II epitopes (about 25–30 amino acids long). They find that encoding a series of these in a plasmid, concatenated, but separated by five glycine-serine repeats, provides good expression of the neoantigens by <i>E. coli</i>.</p><p>They then turned to engineering EcN, a strain of <i>E. coli</i> isolated by Professor Alfred Nissle in 1917 from a young soldier resistant to infectious diarrhea.<span><sup>2</sup></span> Nissle marketed his discovery as a probiotic (Mutaflor®, still commercially available). Thus, Redenti <i>et al</i>. start with a safe, non-pathogenic <i>E. coli</i>, already extensively studied and widely used in humans (albeit orally).</p><p>Finding that their neoantigen plasmids express better in <i>E. coli</i> BL21 than in EcN, they set about modifying EcN to resemble BL21. Curing EcN of cryptic plasmids allows increased expression of the neoantigen-encoding plasmid. They then engineer deletions of two proteases: OmpT, which has roles in biofilm formation and the degradation of complement; and Lon which has pleiotropic roles within the bacterial cell, including oxygen-sensing.<span><sup>3</sup></span> Hence, deleting these proteases, not only reduced degradation of the neoantigen peptides, but also attenuates EcN. Although not discussed by the authors, deletion of the Lon protease may impede the survival of EcN in normal tissues more than in the anoxic core of the tumor, further reducing potential off-target effects. Overall, the authors show that their engineered EcN bacteria show an 80-fold increase in expression of the neoantigen peptides compared with the original EcN, and a 1000-fold increased susceptibility to phagocytosis and clearance from the blood.</p><p>In another stroke of genius, the authors next insert the gene for Listeriolysin O (LLO), a pore-forming protein which allows <i>Listeria</i> to escape into the cytosol after phagocytosis. This has two benefits: improved loading of neoantigen epitopes on MHC class I, and skewing towards a T<sub>H</sub>1 immune response after the sensing of intracytoplasmic bacteria.</p><p>The authors then turn to <i>in vivo</i> experiments to test their neoantigen-expressing, cryptic-plasmid cured, OmpT<sup>−</sup>, Lon<sup>−</sup>, LLO<sup>+</sup> EcN.</p><p>In both of the tumor models, EcN injected i.v. could consistently be cultured from tumors (3–4 days after injection), but could not be cultured from any of the other tissues tested, including the tumor-draining lymph node (TdLN). Despite this, i.v. injection of the EcN bacteria in the CT26 model was sho","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":"103 2","pages":"98-100"},"PeriodicalIF":3.2,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12844","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142929996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hilde Raaphorst, Sinéad Lougheed, Latifa Saou, Nadine D van Kleef, Irma Rensink, Anja ten Brinke, Julian J Freen-van Heeren, Annelies W Turksma
Understanding antigen-specific T-cell responses is crucial for advancing immunotherapies and vaccine development. This study proposes a novel approach combining two complementary assays: the 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay (tracking proliferation over 0–48 h) and the VPD450 dye dilution assay (tracking proliferation over 4–6 days). Integrating these techniques provides additional insights into T-cell proliferation kinetics. Both assays were independently optimized using anti-CD3 and anti-CD28 polyclonal T cell stimulation. 1 μM VPD450 is suitable for assessing T-cell proliferation. The EdU concentration should match the stimulation strength, requiring higher concentrations to efficiently track DNA replication detection during increased cellular division. Day 5 was the optimal read-out day for the EdU incorporation assay. We then combined the VPD450 dye dilution and EdU incorporation assays. As a proof of principle, we stimulated PBMCs from healthy donors with tetanus toxoid to assess antigen-specific T-cell responses. Additionally, we demonstrated the assay's application in drug research by evaluating proliferation in a mixed lymphocyte reaction with abatacept, an agonistic anti-CTLA-4 antibody. This combined approach offers qualitative insights into T-cell proliferation kinetics, beneficial for assessing novel vaccine efficiency or for designing new treatments targeting T cell proliferation, such as in autoimmune settings.
{"title":"Exploring the dynamics of T-cell responses: a combined approach using EdU incorporation and proliferation dye dilution assay","authors":"Hilde Raaphorst, Sinéad Lougheed, Latifa Saou, Nadine D van Kleef, Irma Rensink, Anja ten Brinke, Julian J Freen-van Heeren, Annelies W Turksma","doi":"10.1111/imcb.12845","DOIUrl":"10.1111/imcb.12845","url":null,"abstract":"<p>Understanding antigen-specific T-cell responses is crucial for advancing immunotherapies and vaccine development. This study proposes a novel approach combining two complementary assays: the 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay (tracking proliferation over 0–48 h) and the VPD450 dye dilution assay (tracking proliferation over 4–6 days). Integrating these techniques provides additional insights into T-cell proliferation kinetics. Both assays were independently optimized using anti-CD3 and anti-CD28 polyclonal T cell stimulation. 1 μM VPD450 is suitable for assessing T-cell proliferation. The EdU concentration should match the stimulation strength, requiring higher concentrations to efficiently track DNA replication detection during increased cellular division. Day 5 was the optimal read-out day for the EdU incorporation assay. We then combined the VPD450 dye dilution and EdU incorporation assays. As a proof of principle, we stimulated PBMCs from healthy donors with tetanus toxoid to assess antigen-specific T-cell responses. Additionally, we demonstrated the assay's application in drug research by evaluating proliferation in a mixed lymphocyte reaction with abatacept, an agonistic anti-CTLA-4 antibody. This combined approach offers qualitative insights into T-cell proliferation kinetics, beneficial for assessing novel vaccine efficiency or for designing new treatments targeting T cell proliferation, such as in autoimmune settings.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":"103 2","pages":"178-191"},"PeriodicalIF":3.2,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neurodegeneration and neuroinflammation disorders are mainly the result of the deposition of various proteins, such as α-synuclein, amyloid-β and prions, which lead to the initiation and activation of inflammatory responses. Different chemokines are involved in the infiltration and movement of inflammatory leukocytes into the central nervous system (CNS) that express chemokine receptors. Dysregulation of several members of chemokines has been shown in the CNS, cerebrospinal fluid and peripheral blood of patients who have neurodegenerative disorders. Upon infiltration of various cells, they produce many inflammatory mediators such as cytokines. Besides them, some CNS-resident cells, such as neurons and astrocytes, are also involved in the pathogenesis of neurodegeneration by producing chemokines. In this review, we summarize the role of chemokines and their related receptors in the pathogenesis of neurodegeneration and neuroinflammation disorders, including multiple sclerosis, Parkinson's disease and Alzheimer's disease. Therapeutic strategies targeting chemokines or their related receptors are also discussed in this article.
{"title":"Chemokines in neurodegenerative diseases","authors":"Hashemi Vida, Mehranfar Sahar, Amin Nikdouz, Hosseini Arezoo","doi":"10.1111/imcb.12843","DOIUrl":"10.1111/imcb.12843","url":null,"abstract":"<p>Neurodegeneration and neuroinflammation disorders are mainly the result of the deposition of various proteins, such as α-synuclein, amyloid-β and prions, which lead to the initiation and activation of inflammatory responses. Different chemokines are involved in the infiltration and movement of inflammatory leukocytes into the central nervous system (CNS) that express chemokine receptors. Dysregulation of several members of chemokines has been shown in the CNS, cerebrospinal fluid and peripheral blood of patients who have neurodegenerative disorders. Upon infiltration of various cells, they produce many inflammatory mediators such as cytokines. Besides them, some CNS-resident cells, such as neurons and astrocytes, are also involved in the pathogenesis of neurodegeneration by producing chemokines. In this review, we summarize the role of chemokines and their related receptors in the pathogenesis of neurodegeneration and neuroinflammation disorders, including multiple sclerosis, Parkinson's disease and Alzheimer's disease. Therapeutic strategies targeting chemokines or their related receptors are also discussed in this article.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":"103 3","pages":"275-292"},"PeriodicalIF":3.2,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12843","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142890726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}